Magdeburger Company For Medical Studies & Services GmbH

Research site

Germany Franckestrasse 1, Altstadt, 39104 Magdeburg, Germany

5 trials recruiting
Dermatitis atopic · Neurodermatitis · Hidradenitis
Adults and children

About Specializations

Magdeburger Company For Medical Studies & Services GmbH in Magdeburg, Germany specialises in clinical trials of conditions such as Dermatitis atopic, Neurodermatitis, Hidradenitis, Psoriasis, and other specialisations. This site conducts important research.

Main research areas of the site

Dermatology

The medical center is at the forefront of dermatology research, focusing on innovative treatments for skin conditions. The center's work in this field is driven by a commitment to improving patient outcomes through cutting-edge therapies.

Atopic Dermatitis
Papulopustular Acne
Nonsegmental Vitiligo
Papulopustular Rosacea
Prurigo Nodularis

By conducting rigorous clinical trials, the center contributes significantly to the development of new dermatological treatments, enhancing the quality of life for patients with chronic skin conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Franckestrasse 1, Altstadt39104 MagdeburgGermany

Open in maps ↗

Recruiting now: 5 trials
Conditions studied: 8

More sites in Magdeburg Germany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

15 clinical trials

Vitiligo+2

Recruiting

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Povorcitinib
Sponsor:Incyte Corp.

Contact Research Centre

Hidradenitis

Recruiting

A Study of LAD191 Compared to Placebo and Adalimumab in Adults with Moderate-to-Severe Hidradenitis Suppurativa

Registered drug

A Study of LAD191 Compared to Placebo and Adalimumab in Adults with Moderate-to-Severe Hidradenitis Suppurativa

Registered drug

Germany

Participants:18–64 years
Substances:Adalimumab
Sponsor:Almirall S.A.

Contact Research Centre

Papulopustular rosacea

Recruiting

Study on the Effectiveness and Safety of Ivermectin Cream Compared to a Drug Combination for Patients with Papulopustular Rosacea

Registered drug

Study on the Effectiveness and Safety of Ivermectin Cream Compared to a Drug Combination for Patients with Papulopustular Rosacea

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Ivermectin
Sponsor:Dermapharm AG

Contact Research Centre

Acne

Recruiting

Study on the Effectiveness and Safety of Clindamycin and Tretinoin Gel for Patients with Papulopustular Acne

Registered drug

Study on the Effectiveness and Safety of Clindamycin and Tretinoin Gel for Patients with Papulopustular Acne

Registered drug

Germany

Participants:0–17 years · 18–64 years
Substances:Clindamycin
Sponsor:Dermapharm AG

Contact Research Centre

Acarodermatitis

Recruiting

Study on Treating Scabies with Permethrin and Ivermectin for Patients with Scabies

Registered drugNo placebo

Study on Treating Scabies with Permethrin and Ivermectin for Patients with Scabies

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Ivermectin
Sponsor:INFECTOPHARM Arzneimittel und Consilium GmbH

Contact Research Centre

Psoriasis

Not recruiting

Study on Long-term Safety and Effectiveness of ESK-001 for Patients with Moderate to Severe Plaque Psoriasis

Investigational

Study on Long-term Safety and Effectiveness of ESK-001 for Patients with Moderate to Severe Plaque Psoriasis

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Envudeucitinib
Sponsor:Alumis Inc.

Contact Research Centre

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of ESK-001 and Apremilast for Patients with Moderate to Severe Plaque Psoriasis

Registered drug

Study on the Effectiveness and Safety of ESK-001 and Apremilast for Patients with Moderate to Severe Plaque Psoriasis

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Apremilast
Sponsor:Alumis Inc.

Contact Research Centre

Dermatitis atopic

Not recruiting

Study on the Effects of PF-07275315 and PF-07264660 for Adults with Moderate to Severe Atopic Dermatitis

Investigational

Study on the Effects of PF-07275315 and PF-07264660 for Adults with Moderate to Severe Atopic Dermatitis

Investigational

Germany

Participants:18–64 years · 65+ years
Sponsor:Pfizer Inc.

Contact Research Centre

Vitiligo

Not recruiting

Study of ritlecitinib (50 mg and 100 mg daily) compared to placebo in adults with nonsegmental vitiligo

Registered drug

Study of ritlecitinib (50 mg and 100 mg daily) compared to placebo in adults with nonsegmental vitiligo

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Dexamethasone
Sponsor:Pfizer Inc.

Contact Research Centre

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis

Registered drug

Study on the Effectiveness and Safety of Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis

Registered drug

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Amlitelimab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Dermatitis atopic

Not recruiting

Study on Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis

Registered drug

Study on Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis

Registered drug

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Amlitelimab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Neurodermatitis

Not recruiting

Study on Dupilumab for Itch Relief in Adults with Lichen Simplex Chronicus (Neurodermatitis)

Investigational

Study on Dupilumab for Itch Relief in Adults with Lichen Simplex Chronicus (Neurodermatitis)

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Dupilumab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites